Amgen Halts Development of Brodalumab Save

IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.  Amgen announced Friday (5/22/15) it was no longer going to pursue approval on broadalumab, citing concerns over suicidal ideation and behavioral issues that may lead to restrictive labeling. Both Amgen and Astra-Zeneca have agreed to halt ongoing clinical trials with broadalumab. The future of compound will rest with Astra-Zeneca, who at this time has not indicated a change in its interest in broadalumab.